BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
News & Analysis: BridgeBio Pharma Inc
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
These small-cap biotechs have fallen to bargain prices.
These innovative healthcare companies promise investors a way to benefit from medical breakthroughs without the usual risk.
This pair of healthcare businesses made their public debut in June, but they're already making a big impression.